Correction: PPARγ is essential for protection against nonalcoholic steatohepatitis

Chunhui Wu, Eagle S.h. Chu, C. N. Y. Lam, Alfred S.l. Cheng, C. W. Lee, Vincent Wai‐Sun Wong, Joseph J.�y. Sung, Jun YuGene 2025 · DOI · OpenAlex

Introduction

Nonalcoholic steatohepatitis (NASH) represents a severe progression of fatty liver disease, marked by inflammation and hepatocyte damage that can lead to cirrhosis. This document provides a formal correction to a 2010 study published in Gene Therapy, specifically addressing a mislabeled histological image in Figure 3A. Despite this visual update, the original study's conclusions remain robust: Peroxisome Proliferator-Activated Receptor gamma (PPARγ) serves as a vital molecular safeguard against liver fat accumulation and oxidative stress.

Experimental Approach

To investigate the protective capacity of PPARγ, researchers employed the Methionine-Choline Deficient (MCD) diet in mice, a standard model for inducing rapid steatosis and inflammation. The study utilized adenoviral vectors to deliver the PPARγ gene (Ad-PPARγ) directly to liver cells, comparing results against a control virus (Ad-LacZ). Furthermore, the team explored pharmacological synergy by administering Rosiglitazone (Ros), a PPARγ activator, to determine if enhanced receptor activity could further mitigate disease progression.

Histological and Biochemical Insights

The corrected histological data reaffirms the pathological impact of the MCD diet. In disease control groups, liver tissue exhibits significant lipid droplet accumulation and inflammatory foci.

Histological section of liver tissue from an MCD-fed mouse showing extensive lipid droplets (steatosis) and an inflammatory cluster (arrow).

Treatment with Ad-PPARγ was shown to preserve cellular architecture by reducing these lipid deposits. The study highlights a multi-pronged defense mechanism where PPARγ not only limits fat storage but also reduces markers of cellular death (ALT) and oxidative stress (TBARS).

Quantitative Results

Biochemical assays confirmed the therapeutic efficacy of increasing both the expression and activation of PPARγ. While gene delivery alone provided benefits, the combination of Ad-PPARγ and Rosiglitazone yielded the most significant improvements.

Liver Triglyceride (TG) levels across experimental groups. The MCD diet significantly increases fat accumulation, which is markedly reduced by the combination of Ad-PPARγ gene therapy and Rosiglitazone activation.

Key findings include:

  • Liver Triglycerides: Fat levels dropped from approximately 60 µg/mg in the MCD disease group to 30 µg/mg with combined therapy.
  • Oxidative Stress: TBARS levels, indicating lipid peroxidation, were nearly restored to baseline levels in the treatment group.
  • Liver Damage: Serum ALT levels were reduced by over 50%, signaling a substantial decrease in liver cell death.

Conclusion

This correction ensures the visual evidence accurately reflects the quantitative data. The findings reinforce PPARγ's role as a critical regulator of liver health, suggesting that targeting its expression and activity remains a promising avenue for treating advanced fatty liver diseases like NASH. Future research will focus on translating these findings into clinical therapies, potentially using more targeted agonists to minimize side effects.

Summary updated

BibTeX
@inproceedings{wu2025correction,
  author = {Chunhui Wu and Eagle S.H. Chu and C. N. Y. Lam and Alfred S.L. Cheng and C. W. Lee and Vincent Wai‐Sun Wong and Joseph J.�Y. Sung and Jun Yu and Joseph JY Sung},
  title = {{Correction: PPARγ is essential for protection against nonalcoholic steatohepatitis}},
  booktitle = {Gene},
  year = {2025},
  doi = {10.1038/s41434-025-00568-z},
}
Figure